Oncimmune is to reacquire the China and Hong Kong rights to the EarlyCDT product portfolio from Genostics. The decision was made to provide strategic optionality removing a potential conflict that may have existed if Oncimmune were to access the US capital markets. The immediate financial impact of removing EarlyCDT Lung royalties in China is modest, and we have decreased our revenue estimates by 2.8% and 4.9% in FY’22 and FY’23, respectively. This decision leaves the door open for future value- ....
05 May 2021
China EarlyCDT rights returned
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
China EarlyCDT rights returned
Oncimmune Holdings Plc (ONC:LON) | 30.1 1.1 13.6% | Mkt Cap: 22.3m
- Published:
05 May 2021 -
Author:
Edward Thomason -
Pages:
3
Oncimmune is to reacquire the China and Hong Kong rights to the EarlyCDT product portfolio from Genostics. The decision was made to provide strategic optionality removing a potential conflict that may have existed if Oncimmune were to access the US capital markets. The immediate financial impact of removing EarlyCDT Lung royalties in China is modest, and we have decreased our revenue estimates by 2.8% and 4.9% in FY’22 and FY’23, respectively. This decision leaves the door open for future value- ....